How should I take Dasatinib/Startase?

The administration of Dasatinib should strictly follow the guidance of a doctor, and the plan must be evaluated and formulated by a hematology and oncology expert with experience in the diagnosis and treatment of leukemia. The recommended starting dose for adults with chronic phase chronic myeloid leukemia (CML) is 100 mg orally once a day; while the recommended dose for patients with accelerated phase CML, myeloid or lymphoblastic phase CML, and Ph+ acute lymphoblastic leukemia is 140 mg once a day. Tablets must be swallowed whole and not crushed or chewed to ensure stable drug release and absorption. The medication can be taken in the morning or evening. Whether it is taken with food or not does not affect absorption. However, strong acid inhibitors such as omeprazole should be avoided at the same time to avoid affecting the bioavailability of the drug.

For pediatric patients, the dose of dasatinib needs to be adjusted individually based on body weight. Generally speaking, children weighing 10 to 20kg take 40mg orally once daily, 20 to 30kg takes 60mg, 30 to 45kg takes 70mg, while children weighing more than 45kg use the adult dose of 100mg. Because children's growth changes rapidly, weight should be reassessed and dosage adjusted every three months. For children with dysphagia, it is necessary to follow the doctor's guidance to choose the appropriate method of administration, and do not break or dissolve the tablets without authorization.

During the course of medication, doctors usually monitor blood levels, liver and kidney function, and electrocardiogram regularly to prevent possible adverse reactions such as bone marrow suppression, fluid retention, orQT interval prolongation. Some patients may develop mild edema or pleural effusion in the early stages of treatment, and intervention should be carried out according to the severity. It is recommended to avoid grapefruit-based foods while taking the drug because it may inhibit the CYP3A4 metabolic enzyme, leading to an increase in the blood concentration of the drug, thereby increasing the risk of side effects.

Overall, dasatinib is a highly effective targeted therapy that requires precise management. By strictly following medical instructions, regular review and reasonable monitoring, patients can not only maintain long-term remission, but also significantly improve their quality of life.

Reference materials:https://go.drugbank.com/drugs/DB01254